Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883999 · ClinicalTrials.gov registry record · NA
Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis
A NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01883999 is a NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms that has completed, run by W.L.Gore & Associates. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01883999, a NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
Conditions Studied
Interventions
- DEVICE GORE® EXCLUDER® Iliac Branch Endoprosthesis
Study Locations (1)
New York
- Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-10 |
| Est. Completion | 2021-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01883999
The ClinicalTrials.gov registry entry for NCT01883999 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Aorto-iliac Aneurysms appearing as the primary indexed condition, and to 1 intervention - of which GORE® EXCLUDER® Iliac Branch Endoprosthesis is the first listed.
NCT01883999 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01883999 about?
NCT01883999 is a clinical study titled "Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis". The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
What is the current status of trial NCT01883999?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2013-10. Estimated completion is 2021-06.
What conditions does trial NCT01883999 study?
This clinical trial studies the following conditions: Aorto-iliac Aneurysms, Common Iliac Artery Aneurysms.
What interventions are being tested in trial NCT01883999?
The interventions under investigation include: GORE® EXCLUDER® Iliac Branch Endoprosthesis (DEVICE).
Who is sponsoring clinical trial NCT01883999?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01883999 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aorto-iliac Aneurysms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.